Article | October 28, 2016

Phase I In The Age Of Precision Medicine And Patient Diversity

Source: Medrio
Phase I In The Age Of Precision Medicine And Patient Diversity

By Nick O'Brien

As clinical research evolves and becomes more refined, the industry is coming to acknowledge a simple truth: that everyone is different. A drug that works wonders for one individual may have little to no effect on, or even be detrimental to, another. Alternatively, the discovery that a treatment is ineffective or dangerous in a small group of clinical trial patients may cause the discontinuation of that drug’s development, allowing its potential to help the general population to go undiscovered. The trends toward precision medicine and patient diversity show that the clinical research industry is making stronger efforts to acknowledge the genetic, ethnic, and biological differences among patients that lead to these disparities. Spurring these trends are some startling statistics: some of the highest-grossing medications in the United States work as intended for only 4% of the patients who take them.1